Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Robert H. Spencer"'
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Difelikefalin is a selective kappa opioid receptor agonist that is approved for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis (HD). In this study, we assessed
Externí odkaz:
https://doaj.org/article/deec51e12f794809baa5fbf35205aee0
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 9, Pp 1559-1568 (2023)
Abstract Difelikefalin is a selective kappa opioid receptor agonist approved for treating moderate‐to‐severe pruritus in adults undergoing hemodialysis (HD). Difelikefalin is not a controlled substance under the Controlled Substances Act. This st
Externí odkaz:
https://doaj.org/article/3112332ed4cc40af8b7b02b4c96ead3c
Autor:
Frédérique Menzaghi, Margaret K. Vernon, Maria Mattera, Joshua Cirulli, Warren Wen, Robert H. Spencer, Catherine Munera
Publikováno v:
Kidney Medicine, Vol 5, Iss 9, Pp 100696- (2023)
Rationale & Objective: Despite its prevalence and distress to patients, chronic kidney disease-associated pruritus (CKD-aP) is poorly characterized, which may contribute to the condition’s underdiagnosis and inadequate management. This study aimed
Externí odkaz:
https://doaj.org/article/b58e8d8e6bd54b58bf94836537bc8438
Autor:
Megan J. Shram, Robert H. Spencer, Jenny Qian, Catherine L. Munera, Michael E. Lewis, Jack E. Henningfield, Lynn Webster, Frédérique Menzaghi
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 2, Pp 535-547 (2022)
Abstract Difelikefalin, a selective kappa‐opioid receptor agonist with limited central nervous system penetration, is being developed for the treatment of chronic pruritic conditions. This randomized, double‐blind, active‐ and placebo‐control
Externí odkaz:
https://doaj.org/article/60ec05c898d44489a5a58573d586842c
Autor:
Margaret K. Vernon, Laura L. Swett, Rebecca M. Speck, Catherine Munera, Robert H. Spencer, Warren Wen, Frédérique Menzaghi
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 5, Iss 1, Pp 1-12 (2021)
Plain English summary Itching is a distressing medical condition common in patients with chronic kidney disease, especially those undergoing hemodialysis. The itch often leads to skin damage due to a continuous and uncontrollable urge to scratch. It
Externí odkaz:
https://doaj.org/article/a519096102774252a0bf71989005a36a
Autor:
Steven Fishbane, Vandana Mathur, Michael J. Germain, Shayan Shirazian, Sarbani Bhaduri, Catherine Munera, Robert H. Spencer, Frédérique Menzaghi, Michael Aaronson, Kelly Alford, Ahmed Awad, Premila Bhat, Varshab Broumand, Wesley Calhoun, Riad Darwish, Sohan Dua, Carl Dukes, Ayodele Erinle, Alexander Hadley, John Hsieh, Mohammad Kashif, Nelson Kopyt, Jayant Kumar, Jorge Kusnir, Jean Lee, Essam Maasarani, Richard Miller, M. Reza Mizani, Jesus Navarro, Amber Podoll, Thomas Pohlman, Denise Rivers, Derrick Robinson, Lisa Rich, Arnold Silva, Mark Smith, Joel Topf, James Tumlin, Scott Ungar, Steven Zeig
Publikováno v:
Kidney International Reports, Vol 5, Iss 5, Pp 600-610 (2020)
Introduction: There is an unmet medical need for pruritus associated with chronic kidney disease, a distressing complication characterized by generalized and persistent itch affecting 20% to 40% of patients undergoing hemodialysis. Here we report the
Externí odkaz:
https://doaj.org/article/3af3ad5bc3284ca58e68530fc56bfc4c
Publikováno v:
Journal of the American Academy of Dermatology.
Publikováno v:
Journal of the American Academy of Dermatology. 84:1132-1134
Autor:
Matthew J. Cato, Peter J. Manley, Christopher J. Dinsmore, Jixin Wang, B. Wesley Trotter, M. Brad Nolt, Bing Li, Robert H. Spencer, Mark T. Bilodeau, Gary L. Stump, Scott E. Wolkenberg, Rebecca B. White, Kausik K. Nanda, Laszlo Kiss, George D. Hartman, Craig W. Lindsley, Christopher P. Regan, Stefanie A. Kane, Zhicai Wu, Suzie Yeh, Joseph J. Lynch, Nathan R. Kett
Publikováno v:
Bioorganicmedicinal chemistry letters. 27(4)
Selective inhibition of Kv1.5, which underlies the ultra-rapid delayed rectifier current, IKur, has been pursued as a treatment for atrial fibrillation. Here we describe the discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity versus the
Publikováno v:
Drug and Alcohol Dependence. 171:e86-e87